Ole Isacson
Corporate Officer/Principal bei Harvard Medical School
Vermögen: 387 $ am 31.03.2024
Profil
Ole Isacson is currently the Director of the Neuroregeneration Institute at McLean Hospital, a Professor at Harvard Medical School, and a Member of the Harvard Stem Cell Institute.
He previously served as the Chief Scientific Officer and SVP of Neuroscience R&D at Pfizer Inc. and as the President of the Neural Transplantation and Repair division of the American Society for Neurological Therapeutics.
He was also the President of the International Cell division of the Transplantation Society.
Isacson holds undergraduate and doctorate degrees from the University of Lund.
Bekannte Unternehmensbeteiligungen
Unternehmen | Datum | Anzahl der Aktien | Bewertung | Datum der Bewertung |
---|---|---|---|---|
15.06.2023 | 121 ( 0,00% ) | 387 $ | 31.03.2024 |
Aktive Positionen von Ole Isacson
Unternehmen | Position | Beginn |
---|---|---|
Harvard Medical School | Corporate Officer/Principal | 01.01.2002 |
McLean Hospital, Inc.
McLean Hospital, Inc. Hospital/Nursing ManagementHealth Services McLean Hospital, Inc. provides healthcare services. It offers specialized programs for the research and treatment of psychiatric and neurological illnesses, including: depression, bipolar and psychotic disorders, mood and anxiety disorders, substance abuse, geriatric mental illnesses and child adolescent psychiatric disorders. The company was founded in February, 1811 and is headquartered in Belmont, MA. | Corporate Officer/Principal | 01.01.2010 |
Harvard Stem Cell Institute
Harvard Stem Cell Institute BiotechnologyHealth Technology Harvard Stem Cell Institute provides research regarding stem cells necessary for the understanding of human development and disease and trains next generation stem cell scientists. The company was founded by Doug A. Melton and David T. Scadden in April 2004 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - |
Ehemalige bekannte Positionen von Ole Isacson
Unternehmen | Position | Ende |
---|---|---|
CYCLERION THERAPEUTICS, INC. | Director/Board Member | 19.11.2023 |
PFIZER, INC. | Chief Tech/Sci/R&D Officer | 01.05.2017 |
Transplantation Society | Corporate Officer/Principal | - |
American Society For Neurological Therapeutics | Corporate Officer/Principal | - |
Ausbildung von Ole Isacson
University of Lund | Doctorate Degree |
Erfahrungen
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Beziehungen
Beziehungen ersten Grades
Unternehmen ersten Grades
Herr
Frau
Aufsichtsräte
Führungskräfte
Unternehmensverbindungen
Börsennotierte Unternehmen | 2 |
---|---|
PFIZER, INC. | Health Technology |
CYCLERION THERAPEUTICS, INC. | Health Technology |
Private Unternehmen | 4 |
---|---|
Transplantation Society | |
McLean Hospital, Inc.
McLean Hospital, Inc. Hospital/Nursing ManagementHealth Services McLean Hospital, Inc. provides healthcare services. It offers specialized programs for the research and treatment of psychiatric and neurological illnesses, including: depression, bipolar and psychotic disorders, mood and anxiety disorders, substance abuse, geriatric mental illnesses and child adolescent psychiatric disorders. The company was founded in February, 1811 and is headquartered in Belmont, MA. | Health Services |
Harvard Stem Cell Institute
Harvard Stem Cell Institute BiotechnologyHealth Technology Harvard Stem Cell Institute provides research regarding stem cells necessary for the understanding of human development and disease and trains next generation stem cell scientists. The company was founded by Doug A. Melton and David T. Scadden in April 2004 and is headquartered in Cambridge, MA. | Health Technology |
American Society For Neurological Therapeutics |